|
|
Blood, 1 January 2006, Vol. 107, No. 1, pp. 305-308.
Prepublished online as a Blood First Edition Paper on September 20, 2005; DOI 10.1182/blood-2005-06-2393.
 Previous Article | Table of Contents | Next Article 
NEOPLASIA
Brief report
Bmi-1 is useful as a novel molecular marker for predicting progression of myelodysplastic syndrome and patient prognosis
Keichiro Mihara,
Moniruddin Chowdhury,
Nanae Nakaju,
Sachiko Hidani,
Akihiro Ihara,
Hideo Hyodo,
Shin'ichiro Yasunaga,
Yoshihiro Takihara, and
Akiro Kimura
From the Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima; the Department of Internal Medicine, National Kure Medical Center, Kure; and the Department of Stem Cell Biology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
The International Prognostic Scoring System (IPSS) has been widely used to predict the prognosis of patients with myelodysplastic syndrome (MDS). However, IPSS does not always provide a sufficiently precise evaluation of patients to allow the appropriate choice of clinical interventions. Here, we analyzed the expression of Bmi-1, which is required to regulate the self-renewal in CD34+ cells from 51 patients with cases of MDS and acute myeloid leukemia preceded by MDS (MDS-AML). Higher positivity rate of Bmi-1 was preferentially seen in refractory anemia with excess blasts (RAEB), RAEB in transformation (RAEB-T), and MDS-AML compared with refractory anemia (RA) and RA with ringed sideroblasts (RARS). IPSS score was positively correlated with the percentage of Bmi-1 expression. Patients with RA and RARS with a higher percentage of Bmi-1+ cells showed disease progression to RAEB. Here, we propose Bmi-1 as a novel molecular marker to predict the progression and prognosis of MDS.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
M. Mohty, R. M. Szydlo, A. S. M. Yong, J. F. Apperley, J. M. Goldman, and J. V. Melo
Association between BMI-1 expression, acute graft-versus-host disease, and outcome following allogeneic stem cell transplantation from HLA-identical siblings in chronic myeloid leukemia
Blood,
September 1, 2008;
112(5):
2163 - 2166.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Rizo, B. Dontje, E. Vellenga, G. de Haan, and J. J. Schuringa
Long-term maintenance of human hematopoietic stem/progenitor cells by expression of BMI1
Blood,
March 1, 2008;
111(5):
2621 - 2630.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Hosen, T. Yamane, M. Muijtjens, K. Pham, M. F. Clarke, and I. L. Weissman
Bmi-1-Green Fluorescent Protein-Knock-In Mice Reveal the Dynamic Regulation of Bmi-1 Expression in Normal and Leukemic Hematopoietic Cells
Stem Cells,
July 1, 2007;
25(7):
1635 - 1644.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Mohty, A. S. M. Yong, R. M. Szydlo, J. F. Apperley, and J. V. Melo
The polycomb group BMI1 gene is a molecular marker for predicting prognosis of chronic myeloid leukemia
Blood,
July 1, 2007;
110(1):
380 - 383.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Yang, L. Chai, F. Liu, L. M. Fink, P. Lin, L. E. Silberstein, H. M. Amin, D. C. Ward, and Y. Ma
Bmi-1 is a target gene for SALL4 in hematopoietic and leukemic cells
PNAS,
June 19, 2007;
104(25):
10494 - 10499.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Melchert and A. F. List
Management of RBC-Transfusion Dependence
Hematology,
January 1, 2007;
2007(1):
398 - 404.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L.-B. Song, M.-S. Zeng, W.-T. Liao, L. Zhang, H.-Y. Mo, W.-L. Liu, J.-Y. Shao, Q.-L. Wu, M.-Z. Li, Y.-F. Xia, et al.
Bmi-1 Is a Novel Molecular Marker of Nasopharyngeal Carcinoma Progression and Immortalizes Primary Human Nasopharyngeal Epithelial Cells.
Cancer Res.,
June 15, 2006;
66(12):
6225 - 6232.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
